References

• Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322 (7295); 1154-8.
  
  
• Ahmedzai S, Brooks D. Transdermal Fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. The TTS-Fentanyl Comparative Trial Group. Journal of Pain & Symptom Management. 1997; 13: 254-61.
  
  
• Ans PE Vielvoye-Kerkmeer A Carlien Mattern and Martin P Uitendaal.  Transdermal fentanyl in opioid naïve cancer pain patients; an open trial using transdermal fentanyl for the treatment of chronic cancer pain  in opioid-naïve patients and a group using codeine. Journal of Pain and Symptom Management 2000; 19; 3; 185-192 .
  
  
• Cancerbacup. Freedom from Pain: Pain Management Survey. 2000. WWW.cancerbacup.org.uk
  
  
• Clarke EB, French B, Bilodeau ML, Capasso VC, Edwards A, Empoliti J. Pain management knowledge, attitudes and clinical practice: the impact of nurses' characteristics and education. Journal of Pain & Symptom Management. 1996; 11: 18-31.
  
  
• Curry SH, editor. Drug disposition and pharmacokinetics with a consideration of pharmacological and clinical relationships. 3rd Edition, Oxford: Blackwell Scientific Publications; 1980. p. 202.
  
  
• Davies AN, Bond C. Transdermal fentanyl and the opioid withdrawal syndrome. Palliative Medicine, 1996;10:348
  
  
• Donner B, Zenz M, Thyba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.  Pain 1998; 64; 527-534.
  
  
• Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. Journal of Pain & Symptom Management. 1998; 15: 168-75.
  
  
• Durogesic (Fentanyl transdermal system) Summary of  Product Characteristics Dec 2005.
  
  
• Ellershaw JE. Kinder C. Aldridge J. Allison M. Smith JC. Care of the dying: is pain control compromised or enhanced by continuation of the fentanyl transdermal patch in the dying phase?[see comment]. Journal of Pain & Symptom Management., 2002; 24(4):398-403.
  
  
• Freynhagen R, von Giesen HJ, Busche P, Sabatowski R, Konrad C, Grond S.  Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter, pilot study in outpatients with chronic pain. Journal of Pain & Symptom Management. 2005; 30:3; 289-97. PDF 125 KB
  
  
• Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Gaukroger P, Cousins MJ. The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects . Pain 1989; 37: 193-202.
  
  
• Hunt R. transdermal fentanyl and the opioid withdrawal syndrome. Palliative Medicine, 1996;10: 347-348.
  
  
• Lehmann KA, Zech D. Transdermal fentanyl: clinical pharmacology. Journal of Pain & Symptom Management. 1992; 7 (3 suppl): 8-16.
  
  
• Levin ML, Berry JI, Leiter J. Management of pain in terminally ill patients: physician reports of knowledge, attitudes, and behaviour. Journal of Pain & Symptom Management. 1998; 15, 27-40.
  
  
• Menahem S, Shvartzman P, High-Dose fentanyl Patch for Cancer Pain, Journal of the American Board of Family Practice t 2004; 17, No. 5 , 388-390
  
  
• Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturrisi CE, Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993; 78: 36-43.
  
  
• Scottish Intercollegiate Guideline Network. Control of pain in patients with cancer. SIGN: Edinburgh, 2000 (SIGN publication no.44).
  
  
• Smith J. “Building a safer NHS for patients; improving medication safety”  PL CPhO/2004/1 Department of Health (letter) PDF 19KB
  
  
• Smith J. “Building a safer NHS for patients; improving medication safety”  Ref. 34880 (2004) Department of Health (report) PDF 1MB
  
  
• Twycross R, Wilcock A, Charlesworth S & Dickman A. Palliative Care Formulary 2. Radcliffe Medical Press Ltd. Oxon 2002. p185
  
  
• Welsh J, Reid A, Graham J, Curto J, Macleod K, O'Neill C. Physicians knowledge of transdermal fentanyl. Palliative Medicine 2005; 19, 9-16. PDF 93KB
  
  
• Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief a 10-year prospective study. Pain 1995; 63: 65-76.

Additional Documents

• Prescribing information and a summary of product characteristics WORD DOC 185 KB
  
  
• NOTES FOR GUIDANCE ON THE INVESTIGATION OF BIOAVAILABILITY AND BIOEQUIVALENCE - The European Agency for the Evaluation of Medicinal Products PDF 146KB
  
  
• NOTE FOR GUIDANCE ON MODIFIED RELEASE ORAL TRANSDERMAL DOSAGE FORMS: SECTION II (PHARMACOKINETIC AND CLINICAL EVALUATION) - The European Agency for the Evaluation of Medicinal Products PDF 70KB
  

Adobe Acrobat reader is required to view PDF documents - click on the logo below to install.

previous page